<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350180</url>
  </required_header>
  <id_info>
    <org_study_id>MP-JGH-10-032</org_study_id>
    <nct_id>NCT01350180</nct_id>
  </id_info>
  <brief_title>Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis</brief_title>
  <official_title>A Prospective Study Assessing the Predictive Value of TMPRSS2-ERG Gene Fusion and PTEN Deletion in High Risk Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Tamim Niazi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the biggest problems facing prostate cancer patients and their treating physicians is
      who needs to be treated and when. Common clinical and pathological parameters are useful
      (PSA, Gleason score, etc.) but do not clearly predict who will benefit from treatment and who
      will fail. Genetic markers for tumor aggressivity would be of greater value. The finding that
      the TMPRSS2-ERG gene fusion is associated with an increase risk of cancer progression is
      important. TMPRSS2 is controlled by androgen (testosterone) and ERG is part of a family of
      proteins which have a role in controlling cell growth, cell specialization and producing
      tumors. As a consequence of this gene fusion, production of the ERG protein increases in the
      presence of testosterone and could be key to the development of prostate cancer, resistance
      to treatment and poor outcome. The PTEN gene is known to have a role as a tumor suppressor.
      Its deletion is a contributing factor in the development of prostate cancers and poor
      outcome. The coexistence of the two markers could be associated with a higher risk of
      recurrence.

      To date there have been no studies regarding the presence of either of these two markers or
      their coexistence in high risk prostate cancer patients who, despite radiation therapy and
      androgen suppression, develop biochemical failure (their PSA levels rise once again).
      Patients participating in the PCS IV study (high risk prostate cancer treated with radiation
      therapy plus either 18 or 36 months of hormonal suppression) who have had biochemical failure
      or 3 years of follow-up post hormonal therapy will be approached.

      Tumor blocks from consenting patients will be collected and analyzed for the presence of the
      TMPRSS2-ERG gene fusion and the PTEN deletion at the Pathology Department of the Jewish
      General Hospital. Statistical analysis will be carried out to see whether either or both
      markers are present, whether they are associated with certain clinical and pathological high
      risk factors, and whether they can be used to predict which patients will fail treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with biochemical failure showing the TMPRSS2-ERG gene fusion and/or PTEN deletion</measure>
    <time_frame>recruitment over 2 years</time_frame>
    <description>biopsy samples of patients treated for high risk prostate cancer with radical radiation and hormonal therapy who have either biochemical failure or 3-year post treatment follow-up free of cancer recurrences will be tested for the TMPRSS2-ERG gene fusion and the PTEN deletion. The results between the two groups will be compared to see if either DNA changes are an indicator of disease recurrence.</description>
  </primary_outcome>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        high risk prostate cancer patients having received radical radiation and hormonal therapy
        in either biochemical failure or 3-year post end of hormonal therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with prostate cancer post radical radiation therapy and LHRH agonist treated
             in PCSIV clinical trial

          -  biochemical failure (PSA nadir + 2) or minimum follow-up of 3 years post completion of
             hormonal therapy

          -  high risk group

               1. gleason score 8-10

               2. PSA ≥ 20 ng/ml

               3. T3 or T4
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamim Niazi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Mortimer B. Davis - Jewish General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Riggio</last_name>
    <phone>514-340-8222</phone>
    <phone_ext>26771</phone_ext>
    <email>sriggio@jgh.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital de Gatineau</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Normand</last_name>
      <phone>819-561-8100</phone>
    </contact>
    <investigator>
      <last_name>R Archambault</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM-Notre- Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Lafleur</last_name>
      <phone>514-890-8000</phone>
    </contact>
    <investigator>
      <last_name>J-P Guay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L Roy-Huneault</last_name>
      <phone>514-252-3400</phone>
    </contact>
    <investigator>
      <last_name>C Lemaire</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Riggio</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>26771</phone_ext>
      <email>sriggio@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Tamim Niazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Oerna</last_name>
      <phone>514-934-1934</phone>
    </contact>
    <investigator>
      <last_name>L Souhami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUS - Hôpital Fleurimont - Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Couture</last_name>
      <phone>819-346-1110</phone>
    </contact>
    <investigator>
      <last_name>A Nabid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier régional de Trois-Rivières</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Caron</last_name>
      <phone>819-697-3333</phone>
    </contact>
    <investigator>
      <last_name>F Vincent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUQ, L'Hôtel-Dieu de Québec</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Allard</last_name>
      <phone>418-525-4444</phone>
    </contact>
    <investigator>
      <last_name>A-G Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Tamim Niazi</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>biochemical failure</keyword>
  <keyword>hormonal therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

